论文部分内容阅读
目的分析拉米夫定联合激素治疗乙肝相关性膜性肾病的疗效。方法 70例乙肝相关性膜性肾病患者,根据治疗时所采用方案不同分为对照组(30例)和研究组(40例)。对照组行拉米夫定治疗,研究组在对照组基础上行激素治疗,比较两组生活指标及临床疗效。结果研究组24 h尿蛋白、血白蛋白等生化指标均显著优于对照组,且研究组总有效率(97.50%)显著高于对照组(56.67%),差异均具有统计学意义(P<0.05)。结论拉米夫定联合激素治疗乙肝相关性膜性肾病的疗效显著,值得临床推广应用。
Objective To analyze the curative effect of lamivudine combined with hormone therapy on hepatitis B-associated nephropathy. Methods Seventy patients with hepatitis B-associated membranous nephropathy were divided into control group (n = 30) and study group (n = 40) according to the different regimens adopted during treatment. Control group lamivudine treatment, the study group in the control group based on hormone therapy, compared two groups of life indicators and clinical efficacy. Results The 24 h urine protein, serum albumin and other biochemical indicators were significantly better than the control group, and the total effective rate (97.50%) in the study group was significantly higher than that in the control group (56.67%), the differences were statistically significant (P < 0.05). Conclusion Lamivudine combined with hormone treatment of hepatitis B-related membranous nephropathy significant effect, worthy of clinical application.